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Background. Over half of all women in the world experience anemia during their pregnancy. Our aimwas to investigate the relation
between hemoglobin and iron status examined in second trimester and pregnancy outcome.Methods. In a prospective longitudinal
study, 382 pregnantwomenwere included. Blood sampleswere examined for hematological status and serum ferritin between 16 and
20 weeks and for hemoglobin before delivery. The adverse maternal and perinatal outcomes were determined. Regression analysis
was performed to establish if anemia and low serum ferritin are risk factors for pregnancy complications. Results. There was no
increase of complications in women with mild anemia and in women with depleted iron stores. The finding showed that mild iron
deficiency anemia and depleted iron stores are not risk factors for adverse outcomes in iron supplemented women. Conclusions.
Mild anemia and depleted iron stores detected early in pregnancywere not associatedwith adversematernal and perinatal outcomes
in iron supplemented women.
1. Introduction
Over half of all women in the world experience anemia
during their pregnancy [1–4]. The association between the
gestational age at which anemia is diagnosed and adverse
pregnancy outcomes is an important issue [5, 6]. Some of
the increase in anemia and iron deficiency anemia (IDA)
with gestation is a consequence of the normal physiological
changes of pregnancy [7]. To avoid the difficulties in anemia
detection caused by plasma volume increase, the examination
should be conducted until 20 weeks of gestation.
Findings from the studies on the relationship between
anemia and adverse pregnancy outcome are contradictory.
Several studies have shown that preterm delivery, small for
gestational age, and low birth weight are increased for women
with anemia during the 1st trimester and risk depends on
the severity of the hemoglobin deficit [6, 8–11]. Women
with hemoglobin between 8.0 and 9.9 g/dL had significantly
higher risk for low birth weight, preterm birth, and small for
gestational age than women with hemoglobin between 10.0
and 11.9 g/dL [12]. The observation by Scholl et al. showed
that only iron deficiency anemia, not any other anemia,
was related to preterm birth, which suggests that some iron
specific mechanism may be at play [12].
Severe anemia is also associated with adverse maternal
outcome and may contribute directly or indirectly to a sig-
nificant proportion of maternal cardiac failure, hemorrhage,
and infection. On the other hand, higher rates of placental
problems (abnormal placentation and placental abruption)
were found among the anemic women [13].
The aim of this study was to investigate the relationship
between hemoglobin concentration and serum ferritin and
adverse outcomes. The logistic regression analysis was per-
formed to establish if anemia and low serum ferritin are risk
factors for well-known adverse pregnancy outcome.
2. Methods
2.1. Study Population. A prospective longitudinal study was
performed at the Department of Obstetrics, University
Hospital of Zurich, to determine the relationship between
hemoglobin concentration and serum ferritin and adverse
outcome. The study was approved by the Human Research
Ethics Committee at the Women’s Hospital in Zurich.
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The women were asked for their consent to participate in our
study and the informed consent was obtained before study
enrolment.
The hematological status and serum ferritin were exam-
ined in 382 pregnant women between 16 and 20 pregnancy
weeks and hemoglobin concentration before delivery. All
womenwere presentedwith singleton pregnancies. Exclusion
criteria included chronic renal disease and malignancies and
having a blood transfusion at least 3months before enrolment
in the study.Womenwith hemoglobin (Hb) between 10.0 and
11.0 g/dL received oral iron supplementation. Women with
hemoglobin<10.0 g/dLwere treated directlywith intravenous
iron in the anemia clinic if they agreed with intravenous
therapy.
2.2. Study Criteria. According to current guidelines based
on recommendations of the CDC, anemia in pregnancy is
defined by a hemoglobin value less than 11.0 g/dL in both the
first and third trimesters and less than 10.5 g/dL in the second
trimester [14]. On the basis of our experiences determining
Hb (error of measurement of Hb ±0.5 g/dL) and the related
high intraindividual variations, we chose Hb < 11.0 g/dL as
the cut-off. Iron deficiency anemia was defined as Hb <
11.0 g/dL and a serum ferritin ≤ 15 𝜇g/L. Depleted iron stores
was defined as a serum ferritin < 20𝜇g/L. Anemia for
other reasons was defined as Hb < 11.0 g/dL and ferritin >
15 𝜇g/L. The category anemia for other reasons included the
following: thalassemia and hemoglobinopathies, vitamin B12
deficiency anemia, folic acid deficiency anemia, and chronic
inflammatory diseases (particularly HIV positive women,
active hepatitis B).
The women were divided according to hemoglobin con-
centration and ferritin levels into womenwith iron deficiency
anemia (Hb < 11.0 g/dL and ferritin ≤ 15 𝜇g/L) (Group 1),
women with depleted iron stores without anemia (Hb ≥
11.0 g/dL and ferritin < 20𝜇g/L) (Group 2), women with
anemia for other reasons (Hb < 11.0 g/dL and ferritin >
15 𝜇g/L) (Group 3), and women with normal status (Group
4: control group).
2.3. Laboratory Assessment. Blood samples were collected
by venipuncture. Hb, red blood cells (RBC), hematocrit
(HCT), mean corpuscular volume (MCV), percentage of
red cells, microcytic, macrocytic, hypochromic, and hyper-
chromic erythrocytes, hemoglobin content of reticulocytes
(CHr), and red blood cell distribution width (RDW) were
measured using an ADVIA hematology analyser system
(Bayer Diagnostics, Leverkusen, Germany). Mean corpuscu-
lar hemoglobin (MCH) was automatically calculated from
Hb and RBC. Ferritin was assessed by chemiluminescence
immunoassay (ACS 190; Ciba/Corning Diagnostic Corp.,
Cleveland, OH).
2.4. Maternal and Perinatal Outcomes. Postpartum hemor-
rhage was defined as Hb decrease of more than 3.0 g/dL
on the second day after delivery. Abnormal site of placental
implantation (placenta praevia) and abnormal placental pen-
etration (placenta accreta/increta/percreta) were described
as abnormal placental invasion or abnormal placentation.
Gestational age was determined on the basis of early ultra-
sound examination. Low birth weight (LBW) was defined
as birth weight <2500 g. Preterm birth was defined as birth
before 37 completed weeks of gestation. Preterm premature
rupture of fetal membranes (PPROM) was defined as rupture
of fetal membranes before 37 completed weeks of gestation.
Intrauterine growth restriction (IUGR) was defined as birth
weight below the sex-specific 5th percentile of weights for
gestational age, decreased amniotic fluid volume, or abnor-
mal Doppler. Macrosomia was defined as birth weight above
the sex-specific 95th percentile of weights for gestational age.
The Statistical Package for the Social Sciences (SPSS)
(Version 12.0.1. for Windows, SPSS Inc.) was used for all
data analyses. Demographic characteristics were expressed
as means (±standard deviation) and range. The outcome
variables were expressed as the absolute number (percent-
age). 𝑃 value was based on Fisher’s exact test for categorical
data and the Mann-Whitney𝑈 test for quantitative variables.
Univariate logistic regression analysis was performed to
compute odds ratios with 95% confidence intervals of women
in Groups 1, 2, and 3 versus nonanemic women (Group 4)
for well-known adverse maternal and perinatal outcomes.
No correction for multiple testing was performed when
comparing single groups with nonanemic women. Those 𝑃
values are only descriptive.
3. Results
The demographic and clinical characteristics are shown
in Table 1. Iron deficiency anemia was observed in 6.5%,
depleted iron stores in 32.2%, and anemia for other reasons in
11.8%.Themean gestational age at study enrolment was 16.3±
1.4weeks.Themean hemoglobin concentration at enrolment
was 11.8 ± 0.9 g/dL and serum ferritin was 33.5 ± 27.8 𝜇g/L.
Out of 70 anemic women, only mild anemia was observed
at enrolment. A higher parity was observed in women with
iron deficiency anemia andwith depleted iron stores (Table 1).
Women in Groups 1, 2, and 3 came more often from former
Yugoslavia and developing countries than women in Group 4
(𝑃 = 0.001).
The maternal outcomes are shown in Table 2. The mean
hemoglobin level before delivery was 12.1 ± 1.2 g/dL (7.9–
15.4). The prevalence of anemia before delivery was 9.7%,
namely, mild anemia in 8.8% and moderate anemia in 0.9%
(Hb < 9.0 g/dL). Although iron therapy was given in anemic
women, a significantly lowerHb before deliverywas observed
in these women (𝑃 = 0.001). There was also a significant dif-
ference of hemoglobin concentration before delivery between
women with depleted iron stores and normal women (𝑃 =
0.005). There was no increase of maternal complications in
women with anemia and in women with depleted iron stores.
The mean gestational age at delivery was 38.7 ± 2.9
weeks (25–42) and birth weight was 3320 ± 646 g (730–
5250) (Table 3). Preterm delivery was observed in 7.6%
(29/382), low birth weight in 8.1% (31/382), and perinatal
mortality in 0.5% (2/382). There was a significant difference
of meconium stained amniotic fluid between women with
Journal of Pregnancy 3
Table 1: Demographic and clinical characteristics.
(a)
Group 1 Group 2 Group 3 Group 4 All women
Pregnant women 25/382 (6.5) 123/382 (32.2) 45/382 (11.8) 189/382 (49.5) 382
Maternal age (years) 30.3 ± 5.9(21.2–38.7)
29.7 ± 5.7
(21.2–44.9)
30.1 ± 6.3
(20.2–41.9)
30.8 ± 5.9
(18.9–44.3)
30.3 ± 5.9
(18.9–44.9)
Gravidity 2.8 ± 1.8 (1–7) 2.4 ± 1.4 (1–7) 2.3 ± 1.5 (1–8) 2.3 ± 1.7 (1–14) 2.4 ± 1.6 (1–14)
=1 7/25 (28.0) 36/123 (29.2) 18/45 (40.0) 74/189 (39.2) 135/382 (35.3)
2–4 14/25 (56.0) 77/123 (62.6) 24/45 (53.3) 100/189 (52.9) 215/382 (56.3)
≥5 4/25 (16.0) 10/123 (8.2) 3/45 (6.7) 15/189 (7.9) 32/382 (8.4)
Parity 2.3 ± 1.3 (1–5) 1.9 ± 0.9 (1–5) 1.7 ± 0.8 (1–4) 1.7 ± 1.0 (1–6) 1.8 ± 0.9 (1–6)
=1 9/25 (36.0) 43/123 (35.0) 22/45 (48.9) 101/189 (53.4) 175/382 (45.8)
2-3 12/25 (48.0) 72/123 (58.5) 22/45 (48.9) 78/189 (41.3) 184/382 (48.2)
≥4 4/25 (16.0) 8/123 (6.5) 1/45 (2.2) 10/189 (5.3) 23/382 (6.1)
Gestational age at delivery (wk) 38.6 ± 2.3(30–41)
38.9 ± 1.9
(29–42)
38.7 ± 1.8
(33–41)
38.7 ± 2.6
(25–42)
38.7 ± 2.9
(25–42)
<37 2/25 (8) 7/123 (5.7) 2/45 (4.4) 18/189 (9.5) 29/382 (7.6)
37–42 23/25 (92) 116/123 (94.3) 43/45 (95.6) 171/189 (90.5) 353/382 (92.4)
Gestational age at enrolment (wk) 16.3 ± 1.3 (15–19) 16.4 ± 1.3(15–20) 16.4 ± 1.3 (15–19) 16.2 ± 1.2 (15–19)
16.3 ± 1.4
(15–20)
BMI (kg/m2) 22.9 ± 4.8(18.2–35.5)
23.5 ± 5.5
(15.4–50.9)
24.1 ± 4.3
(17.6–32.6)
24.2 ± 5.1
(17.8–45.2)
23.9 ± 5.1
(15.4–50.9)
Origin of mother
Europe + North America 2/25 (8.0) 37/123 (30.1) 7/45 (15.6) 76/189 (40.2) 122/382 (31.9)
Former Yugoslavia 12/28 (48.0) 49/123 (39.8) 16/45 (35.6) 50/189 (26.5) 127/382 (33.2)
Developing countries 11/25 (44.0) 37/123 (30.1) 22/45 (48.9) 63/189 (33.3) 133/382 (34.8)
Data expressed as mean ± s.d. (range) or number (%).
(b)
P value 1 versus 4 2 versus 4 3 versus 4 1, 2, and 3 versus 4
Maternal age 0.827 0.068 0.336 0.082
Gravidity 0.121 0.144 0.913 0.153
Parity 0.029∗ 0.005∗∗ 0.797 0.006∗
Gestational age at delivery 0.633 0.687 0.485 0.919
BMI 0.19 0.383 0.941 0.31
Origin of mother 0.05 0.038∗ 0.008∗ 0.001∗∗
∗P value < 0.05; ∗∗P value < 0.005.
Group 1: iron deficiency anemia.
Group 2: depleted iron stores.
Group 3: anemia for other reasons.
Group 4: normal status.
depleted iron stores and nonanemic women (1/123 versus
14/189) (𝑃 = 0.006) (Table 3). No difference of low birth
weight, IUGR, pretermdelivery, or PPROMbetween anaemic
and nonanemic women was ascertained. Macrosomia was
more often in women with iron deficiency anemia and with
depleted iron stores (16% and 11.4%).
The logistic regression analysis showed that anemia and
depleted iron stores are not significant risk factors for adverse
pregnancy outcome (Table 4). The upper limits of the 95%
confidence intervals of the odds ratios for preterm delivery,
LBW, IUGR, and caesarean section showed that mild anemia
and depleted iron stores are not associated with those adverse
outcomes in iron supplemented women. Placental abruption,
abnormal placentation, and puerperal infection were too rare
to draw any conclusions.
4. Discussion
The prevalence of anemia and depleted iron stores in the
present study was 50.5% (193/382), namely, anemia in 18.3%
(70/382) and depleted iron stores in 32.2% (123/382). Our
results are in accordance with other studies performed in
European countries [15]. A higher parity was observed in
women with iron deficiency anemia and depleted iron stores.
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Table 2: Maternal outcome (%).
(a)
Group 1 Group 2 Group 3 Group 4 All women
Hb at delivery (g/dL) 10.9 ± 1.1 (8.8–12.7) 12.1 ± 1.2 (7.9–15.4) 11.3 ± 0.9 (9.1–12.9) 12.5 ± 0.9 (9.5–15.1) 12.1 ± 1.2 (7.9–15.4)
Placental abruption 0/25 (0.0) 1/123 (0.8) 0/45 (0.0) 1/189 (0.5) 2/382 (0.5)
Abnormal placentation 2/25 (8.0) 4/123 (3.3) 0/45 (0.0) 2/189 (1.1) 8/382 (2.1)
Preeclampsia, eclampsia 0/25 (0.0) 1/123 (0.8) 3/45 (6.7) 4/189 (2.1) 8/382 (2.1)
Cardiac failure 0/25 (0.0) 0/123 (0.0) 0/45 (0.0) 0/189 (0.0) 0/382 (0.0)
Delivery modus
Nonoperative vaginal delivery 16/25 (64.0) 69/123 (56.1) 23/45 (51.1) 91/189 (48.1) 199/382 (52.1)
Operative vaginal delivery 1/25 (4.0) 9/123 (7.3) 3/45 (6.7) 31/189 (16.4) 44/382 (11.5)
Caesarean section prim. 6/25 (24.0) 25/123 (20.3) 14/45 (31.3) 37/189 (19.6) 82/382 (21.5)
Caesarean section sec. 2/25 (8.0) 20/123 (16.3) 5/45 (11.1) 30/189 (15.9) 57/382 (14.9)
Postpartum hemorrhage 1/25 (4.0) 7/123 (5.7) 6/45 (13.3) 21/189 (11.1) 35/382 (9.2)
Puerperal sepsis 0/25 (0.0) 0/123 (0.0) 0/45 (0.0) 0/189 (0.0) 0/382 (0.0)
Puerperal infection 0/25 (0.0) 6/123 (4.9) 1/45 (2.2) 6/189 (3.2) 13/382 (3.4)
Urinary tract infection 0/25 (0.0) 1/123 (0.8) 0/45 (0.0) 1/189 (0.5) 2/382 (0.5)
Wound infection 0/25 (0.0) 1/123 (0.8) 0/45 (0.0) 2/189 (1.1) 3/382 (0.8)
Mastitis 0/25 (0.0) 2/123 (1.6) 1/45 (2.2) 2/189 (1.1) 5/382 (1.3)
Endometritis 0/25 (0.0) 1/123 (0.8) 0/45 (0.0) 0/189 (0.0) 1/382 (0.3)
Thrombophlebitis 0/25 (0.0) 1/123 (0.8) 0/45 (0.0) 1/189 (0.5) 1/382 (0.3)
Infection of unclear etiology 0/25 (0.0) 1/123 (0.8) 0/45 (0.0) 0/189 (0.0) 1/382 (0.3)
Subinvolution 1/25 (4.0) 3/123 (2.4) 0/45 (0.0) 2/189 (1.1) 6/382 (1.6)
(b)
P value 1 versus 4 2 versus 4 3 versus 4 1, 2, and 3 versus 4
Hb at delivery 0.001∗∗∗ 0.005∗∗ 0.001∗∗∗ 0.001∗∗∗
Placental abruption 1 1 1 1
Abnormal placentation 0.068 0.217 1 0.284
Preeclampsia, eclampsia 1 0.652 0.132 1
Delivery modus 0.211 0.125 0.157 0.021∗
Postpartum hemorrhage 0.482 0.11 0.613 0.217
Puerperal infection 1 0.55 1 1
Subinvolution 0.312 0.386 1 0.685
∗P value < 0.05; ∗∗P value < 0.005; ∗∗∗P value < 0.001.
Depleted iron stores were higher in women from former
Yugoslavia and anemia for other reasons in women from
developing countries.
Mild anemia and depleted iron stores detected early in
pregnancy were not associated with adverse outcomes in iron
supplemented women. In our study, macrosomia was more
often in nondiabetic women with iron deficiency anemia
(16.0%). Early nonexcessive placental hyperplasia in women
with mild anemia might lead to increased nutrition support
in later pregnancy if a stress situation is experienced. To
our knowledge, no studies exist observing the increased
prevalence of macrosomia in women with iron deficiency
anemia.
There is a lot of controversial information about anemia in
pregnancy and adverse outcomes. Two points are important
for assessment of this relationship: the gestational age at
which the determination of hemoglobin is performed and the
degree of anemia.
Hemoglobin and hematocrit decline due to physiologic
expansion of the plasma volume throughout the 1st and 2nd
trimesters [7]. Plasma volume expansion reaches its lowest
point late in the second to early in the third trimester and
then rises again nearer to term. It is thus becoming clear
that the best time to detect any risk associated with maternal
anemia may be early in pregnancy. This was also confirmed
in the following current studies [10, 16]. Any estimation of
hemoglobin concentration taken after 20weeks’ gestationwill
be reasonably representative of the fall induced by pregnancy
[17]. The mean gestational age at enrolment in our study was
16 weeks.
The second important point is the degree of anemia in
pregnancy. This is the reason why there is a lot of con-
troversial information about the relationship between anemia
and adverse outcomes. The extensive literature review pre-
sented strong evidence for an association between maternal
hemoglobin and birth weight as well as between maternal
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Table 3: Perinatal outcome (%).
(a)
Group 1 Group 2 Group 3 Group 4 All women
Gestational age at delivery (wk) 38.6 ± 2.3 38.9 ± 1.9 38.7 ± 1.8 38.7 ± 2.6 38.7 ± 2.9 (25–42)
Birth weight (g) 3412 ± 605 3369 ± 625 3218 ± 546 3299 ± 687 3320 ± 646 (730–5250)
Meconium in amniotic fluid 3/25 (12.0) 1/123 (0.8) 3/45 (6.7) 14/189 (7.4) 21/382 (5.5)
LBW 2/25 (8.0) 7/123 (5.7) 3/45 (6.7) 19/189 (10.1) 31/382 (8.1)
IUGR 0/25 (0.0) 7/123 (5.7) 3/45 (6.7) 12/189 (6.3) 22/382 (5.8)
Macrosomia 4/25 (16.0) 14/123 (11.4) 0/45 (0.0) 15/189 (7.9) 33/382 (8.6)
Preterm delivery 2/25 (8.0) 7/123 (5.7) 2/45 (4.4) 18/189 (9.5) 29/382 (7.6)
PPROM 1/25 (4.0) 2/123 (1.6) 0/45 (0.0) 7/189 (3.7) 10/382 (2.6)
Still birth 0/25 (0.0) 0/123 (0.0) 1/45 (2.2) 0/189 (0.0) 1/382 (0.3)
Neonatal death 0/25 (0.0) 0/123 (0.0) 0/45 (0.0) 1/189 (0.5) 1/382 (0.3)
NICU admissions 0/25 (0.0) 0/123 (0.0) 0/45 (0.0) 1/189 (0.5) 1/382 (0.3)
Apgar score at 1󸀠 8.1 ± 0.8 (6–9) 7.9 ± 0.9 (3–9) 7.9 ± 1.5 (0–10) 7.7 ± 1.3 (1–9) 7.9 ± 1.2 (0–10)
Apgar score at 5󸀠 8.8 ± 0.7 (7–10) 9.0 ± 0.5 (7–10) 8.8 ± 1.5 (0–10) 8.9 ± 0.9 (3–10) 8.9 ± 0.9 (0–10)
Apgar score <5 at 5󸀠 0/25 (0.0) 0/123 (0.0) 1/45 (2.2) 3/189 (1.6) 4/382 (1.0)
(b)
P value 1 versus 4 2 versus 4 3 versus 4 1, 2, and 3 versus 4
Meconium in amniotic fluid 0.428 0.006∗ 1 0.12
LBW 1 0.211 0.583 0.192
IUGR 0.368 1 1 0.666
Macrosomia 0.25 0.324 0.82 0.717
Preterm delivery 1 0.287 0.38 0.179
PPROM 1 0.491 0.351 0.216
Still birth NoS NoS 0.192 1
Neonatal death 1 1 1 0.495
NICU admissions 1 1 1 0.495
Apgar score <5 at 5󸀠 1 0.281 0.577 0.368
∗P value < 0.05.
NoS: no statistics are computed because variable is a constant.
Table 4: Logistic regression analysis of adverse outcomes among anemic women and women with depleted iron stores (Groups 1, 2, and 3)
versus nonanemic women (Group 4).
Adverse outcome Groups 1, 2, and 3 Group 4 O.R. (95% CI) P value
(𝑛 = 193) (𝑛 = 189)
Preterm delivery 11/193 (5.7) 18/189 (9.5) 0.58 (0.26–1.25) 0.162
LBW 12/193 (6.2) 19/189 (10.1) 0.59 (0.28–1.26) 0.174
IUGR 10/193 (5.2) 12/189 (6.4) 0.81 (0.34–1.91) 0.625
Caesarean section 72/193 (37.3) 67/189 (35.5) 0.92 (0.60–1.43) 0.75
hemoglobin and preterm delivery [18]. Mild anemia, which
was present in our study, was not associated with adverse out-
comes in iron supplemented women. Therefore, we assume
that iron supplementation had a protective effect on adverse
outcome. On the other hand, severe maternal anemia, par-
ticularly in the first trimester, is associated with adverse out-
comes, namely, preterm birth, low birth weight, intrauterine
growth restriction, low Apgar score, and operative deliveries
[5, 9, 10, 16, 19, 20]. The association between the degree
of anemia and adverse outcome was investigated by many
studies, in which this association was confirmed [5, 9, 10,
21]. Extremely high maternal mortality (6.2%) and perinatal
mortality (60%) were determined in the study by Patra et al.,
in which severematernal anemia was determined in the third
trimester [20].
A meta-analysis of studies on the association between
hemoglobin concentration and adverse outcome, conducted
between 1985 and 1998, showed that maternal anemia during
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early pregnancy is associated with slightly increased preterm
delivery but not with significantly increased low birth weight
or with fetal growth restriction [16]. This meta-analysis
did not consider the degree of anemia nor did it use dif-
ferent parameters for the definition of anemia. Generally,
the hematological parameters and criteria for anemia differ
widely. Some authors use hematocrit <33% as criteria for
anemia [22], and others use hemoglobin concentrationwith a
different cut-off, namely, less than 11.0 g/dL, 10.5, or 10.0 g/dL
[5, 6, 8–10, 17, 19]. We defined anemia as hemoglobin
concentration of 11.0 g/dL or less, since we previously saw
high intraindividual variations between Hb 10.5 and 11.0 g/dL
and there was a large group of women with hemoglobin
between 10.5 and 10.9 g/dL (39/382; 10.2%).
The limitation of our study is the absence of CRP deter-
mination, since ferritin is a marker of inflammation. Conse-
quently, high serum ferritin could actually be a false positive
in patients with inflammation. The second disadvantage is
the lack of any comparison of our results with an untreated
group of anemic women. However, if we compare our results
with other studies, we can say that iron supplementation
had a protective effect on adverse pregnancy outcome. Since
we wished to simulate normal supplementation, the women
did not have to return any residual supplementation. Thus,
compliance was not monitored in this study.
Systematic iron prophylaxis and iron-folic acid supple-
mentation during pregnancy has been debated [23–26]. The
first choice in the prophylaxis of iron deficiency anemia for
almost all women is oral iron replacement because of its
effectiveness, safety, and low cost [24]. However, in practice,
physicians are frequently faced with poor compliance, which
can lead to anemia. The second choice is intravenous iron
supplementation with no drug-related serious adverse effects
[25]. The commonly cited disadvantages of intravenous iron
supplementation are high cost and the invasive nature of the
procedure.
We recommend screening for hemoglobin and iron status
in early pregnancy. When there is a good compliance with
iron supplementation and the pregnancy is uncomplicated,
there is no need for hematological tests during further pre-
natal visits, even in cases of mild iron deficiency anemia and
depleted iron stores detected in early pregnancy. One clear set
of hematological test results early in pregnancy indicates that
there is no increased risk of adverse maternal and perinatal
outcomes due to mild iron deficiency anemia and depleted
iron stores in iron supplemented women; further testing later
in pregnancy is therefore superfluous.
5. Conclusions
Mild anemia and depleted iron stores detected early in
pregnancy were not associated with adverse maternal and
perinatal outcomes.
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